Convatec collaborates with AbbVie for VYALEV™ therapy for the treatment of advanced Parkinson’s disease in the United States

• Convatec’s Neria™ Guard infusion device is used for continuous subcutaneous infusion for a wide range of pharmaceuticals
• Convatec’s Neria™ Guard will be used to deliver AbbVie’s VYALEV™ therapy (foscarbidopa and foslevodopa) in the United States, following FDA approval^1,2
• A version of VYALEV™, known as PRODUODOPA®, was previously approved outside of the United States, and is available for the treatment of advanced Parkinson’s disease in the European Union (EU), Canada and Japan^3,4

London, UK, 21 October 2024 - Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, builds on its rich heritage in the design and manufacturing of high-quality infusion set technologies for continuous subcutaneous treatments for conditions such as advanced Parkinson’s disease¹.

Convatec welcomes further regulatory approvals to support our collaboration with AbbVie, a leading global biopharmaceutical company.

VYALEV™ has now been approved by the United States Food and Drug Administration (FDA) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. The subcutaneous method of administration uses the Convatec Neria™ Guard infusion set.

VYALEV™ is the first and only subcutaneous 24-hour infusion of a levodopa-based therapy for the treatment of advanced Parkinson's disease to be launched in the US². The infusion set can remain in place for up to 3 days while the medication is infused continuously². The Neria™ Guard infusion set will be used together with a portable infusion pump and the VYALEV™ medication. 

Kjersti Grimsrud, President & Chief Operating Officer, Infusion Care at Convatec said, “This is another important development for patients living with a chronic disease. In making our user-friendly infusion set, Neria™ Guard, available for use with a wide range of pharmaceuticals including VYALEV™ in the US market, we’re extending access to this pioneering technology significantly.”

About Neria™ Guard

Neria™ Guard is an all-in-one infusion set with fully automatic insertion at the touch of a button¹. The infusion set connects to a pump on one end and the user’s body on the other end, to deliver medication into the subcutaneous tissue continuously. The retractable needle can provide increased comfort* during the insertion of the small soft cannula situated in the skin and can help prevent accidental needle-stick incidents¹. Neria™ Guard's easy and intuitive insertion technique¹ protects against user errors¹ and may help support use at home and encourage independence in patients’ everyday lives.⁵ Convatec Neria™ Guard infusion set is indicated for subcutaneous infusion of medication.

*Compared to a steel needle.

For information about Neria™ Guard, please refer to the instructions for use that come with the product.

Contacts
Analysts & Investors:    ir@convatec.com
Media:             mediarelations@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch
Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care, and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec revenues in 2023 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com

AP-69622-GBL-ENG-v2
Produodopa is a registered trademark of AbbVie.
Vyalev is a trademark of AbbVie.
Neria is a trademark of Unomedical A/S, a wholly owned subsidiary of Convatec

References:
1. Convatec Data on File, Unomedical A/S. (D012-002912), 20.1.2023.
2. VYALEV FDA Approval https://news.abbvie.com/2024-10-17-U-S-FDA-Approves-VYALEV-TM-foscarbidopa-and-foslevodopa-for-Adults-Living-with-Advanced-Parkinsons-Disease on October 17, 2024
3. AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union, 9.1.2024.
4. AbbVie’s VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson’s Disease in Canada, 8.2.2024
5. Elizabeth Hillman. Examining the use of sharp-free subcutaneous infusion devices with apomorphine. British Journal of Neuroscience Nursing, August/September 2020 Vol 16 No 4.